The Detection of Lung Cancer Cell Profiles in Mediastinal Lymph Nodes Using a Hematological Analyzer and Flow Cytometry Method

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Feb 13

PMID 39941799

Authors

Iwona Kwiecien

Elzbieta Rutkowska

Agata Raniszewska

Rafal Sokolowski

Joanna Bednarek

Karina Jahnz-Rozyk

Piotr Rzepecki

Affiliations

Soon will be listed here.

Abstract

The presence of metastases in mediastinal lymph nodes (LNs) is essential for planning lung cancer treatment and assessing anticancer immune responses. The aim of the study was to assess LNs for the presence of neoplastic cells and evaluate lung cancer-selected antigen expression. LN aspirates were obtained during an EBUS/TBNA procedure. The cells were analyzed using a hematological analyzer and flow cytometry. It was possible to indicate the presence of cells characterized by high fluorescence connected with high metabolic activity using a hematological analyzer and to determine their non-hematopoietic origin using flow cytometry. Using these methods together, we detected very quickly a high proportion of cancer cells in LNs. We noticed that it was possible to determine a high expression of EpCAM, TTF-1, Ki67, cytokeratin, HER, and differences between non-small-cell (NSCLC) and small-cell lung cancer (SCLC) for the antigens MUC-1, CD56, HLA-DR, CD39, CD184, PD-L1, PD-L2 and CTLA-4 on tumor cells. We report, for the first time, that the detection of tumor cells in LNs with the expression of specific antigens is easy to evaluate using a hematological analyzer and flow cytometry in EBUS/TBNA samples. Such precise characteristics of non-hematopoietic cells in LNs may be of great diagnostic importance in the detection of micrometastases.

References

Figueiredo V, Guerreiro Cardoso P, Jacomelli M, Santos L, Minata M, Terra R . EBUS-TBNA versus surgical mediastinoscopy for mediastinal lymph node staging in potentially operable non-small cell lung cancer: a systematic review and meta-analysis. J Bras Pneumol. 2020; 46(6):e20190221. DOI: 10.36416/1806-3756/e20190221. View

Domagala-Kulawik J . New Frontiers for Molecular Pathology. Front Med (Lausanne). 2019; 6:284. PMC: 6904313. DOI: 10.3389/fmed.2019.00284. View

Dinsdale R, Devi A, Hampson P, Wearn C, Bamford A, Hazeldine J . Changes in novel haematological parameters following thermal injury: A prospective observational cohort study. Sci Rep. 2017; 7(1):3211. PMC: 5468303. DOI: 10.1038/s41598-017-03222-w. View

Sun Z, Li P, Wu Z, Li B, Li W, Zhao M . Circulating CD45EpCAM cells as a diagnostic marker for early-stage primary lung cancer. Front Med Technol. 2022; 4:982308. PMC: 9487715. DOI: 10.3389/fmedt.2022.982308. View

Paulsen E, Kilvaer T, Rakaee M, Richardsen E, Hald S, Andersen S . CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunol Immunother. 2017; 66(11):1449-1461. PMC: 5645427. DOI: 10.1007/s00262-017-2039-2. View

Wopereis S, Walter L, Vieira D, Ribeiro A, Fernandes B, Wilkens R . Evaluation of ER, PR and HER2 markers by flow cytometry for breast cancer diagnosis and prognosis. Clin Chim Acta. 2021; 523:504-512. DOI: 10.1016/j.cca.2021.11.005. View

Yamamoto S, Nakayama M . Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA): revolutionizing the landscape of lung disease diagnostics. J Med Ultrason (2001). 2023; 51(2):245-251. DOI: 10.1007/s10396-023-01391-y. View

Tantanate C, Klinbua C . Performance Evaluation of High Fluorescence Lymphocyte Count: Comparability to Atypical Lymphocyte Count and Clinical Significance. Lab Med. 2018; 49(4):362-368. DOI: 10.1093/labmed/lmy030. View

Li Z, Li F, Pan C, He Z, Pan X, Zhu Q . Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma. Lung Cancer. 2021; 154:69-75. DOI: 10.1016/j.lungcan.2021.02.009. View

10.

Li Y, Yang R, Chen L, Wu S . CD38 as an immunomodulator in cancer. Future Oncol. 2020; 16(34):2853-2861. DOI: 10.2217/fon-2020-0401. View

11.

Kim J, Kim H, Kim B, Han B, Choi D, Kwon J . Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. J Cancer. 2018; 9(22):4279-4286. PMC: 6277629. DOI: 10.7150/jca.26830. View

12.

Martowicz A, Seeber A, Untergasser G . The role of EpCAM in physiology and pathology of the epithelium. Histol Histopathol. 2015; 31(4):349-55. DOI: 10.14670/HH-11-678. View

13.

Ko J, Winslow M, Sage J . Mechanisms of small cell lung cancer metastasis. EMBO Mol Med. 2020; 13(1):e13122. PMC: 7799359. DOI: 10.15252/emmm.202013122. View

14.

Jones A, Tailor H, Liesner R, Machin S, Briggs C . The value of the white precursor cell channel (WPC) on the Sysmex XN-1000 analyser in a specialist paediatric hospital. J Clin Pathol. 2014; 68(2):161-5. DOI: 10.1136/jclinpath-2014-202640. View

15.

Camidge D, Doebele R, Kerr K . Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019; 16(6):341-355. DOI: 10.1038/s41571-019-0173-9. View

16.

Rutkowska E, Kwiecien I, Raniszewska A, Sokolowski R, Bednarek J, Jahnz-Rozyk K . New Neutrophil Parameters in Diseases with Various Inflammatory Processes. Biomedicines. 2024; 12(9). PMC: 11429323. DOI: 10.3390/biomedicines12092016. View

17.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

18.

Petrone J, Jackups Jr R, Eby C, Shimer G, Anderson J, Frater J . Blast flagging of the Sysmex XN-10 hematology analyzer with supervised cell image analysis: Impact on quality parameters. Int J Lab Hematol. 2019; 41(5):601-606. DOI: 10.1111/ijlh.13069. View

19.

Passarelli A, Aieta M, Sgambato A, Gridelli C . Targeting Immunometabolism Mediated by CD73 Pathway in -Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance. Front Immunol. 2020; 11:1479. PMC: 7371983. DOI: 10.3389/fimmu.2020.01479. View

20.

Schuff-Werner P, Kohlschein P, Maroz A, Linssen J, Dreissiger K, Burstein C . Performance of the XN-2000 WPC channel-flagging to differentiate reactive and neoplastic leukocytosis. Clin Chem Lab Med. 2016; 54(9):1503-10. DOI: 10.1515/cclm-2015-1105. View